Sibel Isal1, Guillaume Gauchotte2, Fabien Rech3,4, Marie Blonski4,5, Sophie Planel6, Mohammad B Chawki1, Gilles Karcher1, Pierre-Yves Marie1,7, Luc Taillandier4,5, Antoine Verger1,8. 1. 1 Department of Nuclear Medicine & Nancyclotep Imaging platform, CHRU Nancy, Lorraine University , Nancy , France. 2. 2 Department of Pathology, CHU-Nancy, INSERM , Nancy , France. 3. 3 Department of Neurosurgery, CHU-Nancy , Nancy , France. 4. 4 Centre de Recherche en Automatique de Nancy CRAN, Université de Lorraine , Nancy , France. 5. 5 Department of Neuro-oncology, CHU-Nancy , Nancy , France. 6. 6 Department of Neuro-radiology, CHU-Nancy , Nancy , France. 7. 7 INSERM U1116, Lorraine University , Nancy , France. 8. 8 IADI, INSERM U1254, Lorraine University , Nancy , France.
Abstract
OBJECTIVE: In diffuse Grade II-III gliomas, a high 3,4-dihydroxy-6-(18F)-fluoro-L-phenylalanine (18F-FDOPA) positron emission tomography (PET) uptake, with a standardized uptake value (SUVmax)/contralateral brain tissue ratio greater than 1.8, was previously found to be consistently associated with the presence of an isocitrate dehydrogenase (IDH) mutation, whereas this mutation is typically associated with a better prognosis. This pilot study was aimed to ascertain the prognostic value of this high 18F-FDOPA uptake in diffuse Grade II-III gliomas with regard to the velocity of diameter expansion (VDE), which represents an established landmark of better prognosis when below 4 mm per year. METHODS: 20 patients (42 ± 10 years, 10 female) with newly-diagnosed diffuse Grade II-III gliomas (17 with IDH mutation) were retrospectively included. All had a 18F-FDOPA PET, quantified with SUVmax ratio, along with a serial MRI enabling VDE determination. RESULTS: SUVmax ratio was above 1.8 in 5 patients (25%) all of whom had a VDE <4 mm/year (100%) and IDH mutation (100%). Moreover, a SUVmax ratio above 1.8 was associated with higher rates of VDE <4 mm/year in the overall population (45 vs 0%, p = 0.04) and also in the subgroup of patients with IDH mutation (45 vs 0%, p = 0.10). CONCLUSION: This pilot study shows that in diffuse Grade II-III gliomas, a high 18F-FDOPA uptake would be predictive of low tumour growth, with a different prognostic significance than IDH mutation. Advances in knowledge: 18F-FDOPA PET in a single session imaging could have prognostic value in initial diagnosis of diffuse Grade II-III gliomas.
OBJECTIVE: In diffuse Grade II-III gliomas, a high 3,4-dihydroxy-6-(18F)-fluoro-L-phenylalanine (18F-FDOPA) positron emission tomography (PET) uptake, with a standardized uptake value (SUVmax)/contralateral brain tissue ratio greater than 1.8, was previously found to be consistently associated with the presence of an isocitrate dehydrogenase (IDH) mutation, whereas this mutation is typically associated with a better prognosis. This pilot study was aimed to ascertain the prognostic value of this high 18F-FDOPA uptake in diffuse Grade II-III gliomas with regard to the velocity of diameter expansion (VDE), which represents an established landmark of better prognosis when below 4 mm per year. METHODS: 20 patients (42 ± 10 years, 10 female) with newly-diagnosed diffuse Grade II-III gliomas (17 with IDH mutation) were retrospectively included. All had a 18F-FDOPA PET, quantified with SUVmax ratio, along with a serial MRI enabling VDE determination. RESULTS: SUVmax ratio was above 1.8 in 5 patients (25%) all of whom had a VDE <4 mm/year (100%) and IDH mutation (100%). Moreover, a SUVmax ratio above 1.8 was associated with higher rates of VDE <4 mm/year in the overall population (45 vs 0%, p = 0.04) and also in the subgroup of patients with IDH mutation (45 vs 0%, p = 0.10). CONCLUSION: This pilot study shows that in diffuse Grade II-III gliomas, a high 18F-FDOPA uptake would be predictive of low tumour growth, with a different prognostic significance than IDH mutation. Advances in knowledge: 18F-FDOPA PET in a single session imaging could have prognostic value in initial diagnosis of diffuse Grade II-III gliomas.
Authors: Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn Journal: Neuro Oncol Date: 2016-04-21 Impact factor: 12.300
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: A Verger; Ph Metellus; Q Sala; C Colin; E Bialecki; D Taieb; O Chinot; D Figarella-Branger; E Guedj Journal: Eur J Nucl Med Mol Imaging Date: 2017-03-14 Impact factor: 9.236
Authors: Zachary J Reitman; Genglin Jin; Edward D Karoly; Ivan Spasojevic; Jian Yang; Kenneth W Kinzler; Yiping He; Darell D Bigner; Bert Vogelstein; Hai Yan Journal: Proc Natl Acad Sci U S A Date: 2011-02-02 Impact factor: 12.779
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088
Authors: Olivia Kertels; Almuth F Kessler; Milena I Mihovilovic; Antje Stolzenburg; Thomas Linsenmann; Samuel Samnick; Stephanie Brändlein; Camelia Maria Monoranu; Ralf-Ingo Ernestus; Andreas K Buck; Mario Löhr; Constantin Lapa Journal: Mol Imaging Biol Date: 2019-12 Impact factor: 3.488
Authors: Zezhong Ye; Richard L Price; Xiran Liu; Joshua Lin; Qingsong Yang; Peng Sun; Anthony T Wu; Liang Wang; Rowland H Han; Chunyu Song; Ruimeng Yang; Sam E Gary; Diane D Mao; Michael Wallendorf; Jian L Campian; Jr-Shin Li; Sonika Dahiya; Albert H Kim; Sheng-Kwei Song Journal: Clin Cancer Res Date: 2020-07-21 Impact factor: 12.531
Authors: Maike Kern; Timo A Auer; Uli Fehrenbach; Yasemin Tanyildizi; Thomas Picht; Martin Misch; Edzard Wiener Journal: Neuroradiol J Date: 2020-01-19
Authors: Hiroyuki Tatekawa; Hiroyuki Uetani; Akifumi Hagiwara; Jingwen Yao; Talia C Oughourlian; Issei Ueda; Catalina Raymond; Albert Lai; Timothy F Cloughesy; Phioanh L Nghiemphu; Linda M Liau; Shadfar Bahri; Whitney B Pope; Noriko Salamon; Benjamin M Ellingson Journal: J Neurooncol Date: 2021-03-11 Impact factor: 4.130